Homologous recombination repair (HRR) genes and overall survival prognosis within the STRATOS-P classification in metastatic hormone-sensitive prostate cancer (mHSPC).
Retrospective analysis assesses overall survival linked to HRR and MMR gene mutations in mHSPC, indicating prognosis implications.
Key Points
This research aims to explore the impact of genomic alterations in HRR and MMR genes on survival prognosis in metastatic hormone-sensitive prostate cancer.
Retrospective cross-sectional study of veterans diagnosed with metastatic hormone-sensitive prostate cancer (n=4401).
Tumors categorized based on the STRATOS-P classification assessing oncogenic alterations.
Overall survival analyzed using a multivariate Cox model adjusting for age, comorbidities, and PSA levels.
23% of mHSPC patients had oncogenic alterations in HRR or MMR genes, revealing worse prognosis when compared to STRATOS-P-Favorable tumors.
Patients with specific gene alterations like BRCA2 and CDK12 showed higher hazard ratios indicating worse overall survival.
Overall, HRR and MMR alterations correlate with intermediate risk prognosis in mHSPC under STRATOS-P classification.